MAPK reactivation appears to be a common feature of melanoma treatment resistance to double-agent treatment as shown in earlier DNA or RNA sequencing studies, in which mutational mechanisms such as amplifications of mutant BRAF, mutations in NRAS, and mutations in phosphoinositide kinase (PI3K)/Akt pathway were common drivers of pathway reactivation43–46. This evidence concerns the gene NRAS and melanoma.